• Something wrong with this record ?

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

A. Chanan-Khan, P. Cramer, F. Demirkan, G. Fraser, RS. Silva, S. Grosicki, A. Pristupa, A. Janssens, J. Mayer, NL. Bartlett, MS. Dilhuydy, H. Pylypenko, J. Loscertales, A. Avigdor, S. Rule, D. Villa, O. Samoilova, P. Panagiotidis, A. Goy, A....

. 2016 ; 17 (2) : 200-11. [pub] 20151205

Language English Country England, Great Britain

Document type Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

E-resources Online Full text

NLK ProQuest Central from 2000-09-01 to 2 months ago
Nursing & Allied Health Database (ProQuest) from 2000-09-01 to 2 months ago
Health & Medicine (ProQuest) from 2000-09-01 to 2 months ago
Public Health Database (ProQuest) from 2000-09-01 to 2 months ago

BACKGROUND: Most patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma relapse after initial therapy. Bendamustine plus rituximab is often used in the relapsed or refractory setting. We assessed the efficacy and safety of adding ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rituximab in patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma. METHODS: The HELIOS trial was an international, double-blind, placebo-controlled, phase 3 study in adult patients (≥18 years of age) who had active chronic lymphocytic leukaemia or small lymphocytic lymphoma with measurable lymph node disease (>1·5 cm) by CT scan, and had relapsed or refractory disease following one or more previous lines of systemic therapy consisting of at least two cycles of a chemotherapy-containing regimen, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and adequate bone marrow, liver, and kidney function. Patients with del(17p) were excluded because of known poor response to bendamustine plus rituximab. Patients who had received previous treatment with ibrutinib or other BTK inhibitors, refractory disease or relapse within 24 months with a previous bendamustine-containing regimen, or haemopoietic stem-cell transplant were also excluded. Patients were randomly assigned (1:1) by a web-based system to receive bendamustine plus rituximab given in cycles of 4 weeks' duration (bendamustine: 70 mg/m(2) intravenously on days 2-3 in cycle 1, and days 1-2 in cycles 2-6; rituximab: 375 mg/m(2) on day 1 of cycle 1, and 500 mg/m(2) on day 1 of cycles 2-6 for a maximum of six cycles) with either ibrutinib (420 mg daily orally) or placebo until disease progression or unacceptable toxicity. Patients were stratified according to whether they were refractory to purine analogues and by number of previous lines of therapy. The primary endpoint was independent review committee (IRC)-assessed progression-free survival. Crossover to ibrutinib was permitted for patients in the placebo group with IRC-confirmed disease progression. Analysis was by intention-to-treat and is continuing for further long-term follow-up. The trial is registered with ClinicalTrials.gov, number NCT01611090. FINDINGS: Between Sept 19, 2012, and Jan 21, 2014, 578 eligible patients were randomly assigned to ibrutinib or placebo in combination with bendamustine plus rituximab (289 in each group). The primary endpoint was met at the preplanned interim analysis (March 10, 2015). At a median follow-up of 17 months (IQR 13·7-20·7), progression-free survival was significantly improved in the ibrutinib group compared with the placebo group (not reached in the ibrutinib group (95% CI not evaluable) vs 13·3 months (11·3-13·9) in the placebo group (hazard ratio [HR] 0·203, 95% CI 0·150-0·276; p<0·0001). IRC-assessed progression-free survival at 18 months was 79% (95% CI 73-83) in the ibrutinib group and 24% (18-31) in the placebo group (HR 0·203, 95% CI 0·150-0·276; p<0·0001). The most frequent all-grade adverse events were neutropenia and nausea. 222 (77%) of 287 patients in the ibrutinib group and 212 (74%) of 287 patients in the placebo group reported grade 3-4 events; the most common grade 3-4 adverse events in both groups were neutropenia (154 [54%] in the ibrutinib group vs 145 [51%] in the placebo group) and thrombocytopenia (43 [15%] in each group). A safety profile similar to that previously reported with ibrutinib and bendamustine plus rituximab individually was noted. INTERPRETATION: In patients eligible for bendamustine plus rituximab, the addition of ibrutinib to this regimen results in significant improvements in outcome with no new safety signals identified from the combination and a manageable safety profile. FUNDING: Janssen Research & Development.

1st Department of Propedeutic Medicine University of Athens Athens Greece

Center for CLL University of Pennsylvania Philadelphia PA USA

Department 1 of Internal Medicine and German CLL Study Group University of Cologne Cologne Germany

Department 1 of Internal Medicine Center of Integrated Oncology University of Cologne and Cologne Cluster of Excellence in Cellular Stress Responses in Aging Associated Diseases Cologne Germany

Department of Cancer Prevention Faculty of Public Health Silesian Medical University Katowice Poland

Department of Haematology Derriford Hospital Plymouth UK

Department of Hematology Cherkassy Regional Oncological Center Cherkassy Ukraine

Department of Hematology Fundaleu Buenos Aires Argentina

Department of Hematology Karolinska University Hospital Department of Oncology Pathology Karolinska Institutet Stockholm Sweden

Department of Internal Medicine Hematology and Oncology Masaryk University Hospital Brno Jihlavska Brno Czech Republic

Division of Hematology and Bone Marrow Transplantation Chaim Sheba Medical Center Tel Hashomer and Sackler School of Medicine University of Tel Aviv Tel Aviv Israel

Division of Hematology Dokuz Eylul University Izmir Turkey

Division of Medical Oncology British Columbia Cancer Agency Vancouver BC Canada

Hematology Department Hospital Universitario La Princesa IIS IP Madrid Spain

Hôpital Haut Lévêque Bordeaux Pessac France

IEP São Lucas Hemomed Oncologia e Hematologia São Paulo Brazil

Janssen Research and Development High Wycombe UK

Janssen Research and Development Raritan NJ USA

Janssen Research and Development Spring House PA USA

John Theurer Cancer Center at Hackensack University Medical Center Hackensack NJ USA

Juravinski Cancer Centre McMaster University Hamilton ON Canada

Mayo Clinic Cancer Center Jacksonville FL USA

Nizhny Novogorod Regional Clinical Hospital Nizhny Novogorod Russia

Regional Clinical Hospital Ryazan Russia

Universitaire Ziekenhuizen Leuven Leuven Belgium

Washington University School of Medicine Siteman Cancer Center St Louis MO USA

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020100
003      
CZ-PrNML
005      
20240418102314.0
007      
ta
008      
160722s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(15)00465-9 $2 doi
024    7_
$a 10.1016/S1470-2045(15)00465-9 $2 doi
035    __
$a (PubMed)26655421
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Chanan-Khan, Asher $u Mayo Clinic Cancer Center, Jacksonville, FL, USA. Electronic address: Chanan-Khan.Asher@mayo.edu.
245    10
$a Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study / $c A. Chanan-Khan, P. Cramer, F. Demirkan, G. Fraser, RS. Silva, S. Grosicki, A. Pristupa, A. Janssens, J. Mayer, NL. Bartlett, MS. Dilhuydy, H. Pylypenko, J. Loscertales, A. Avigdor, S. Rule, D. Villa, O. Samoilova, P. Panagiotidis, A. Goy, A. Mato, MA. Pavlovsky, C. Karlsson, M. Mahler, M. Salman, S. Sun, C. Phelps, S. Balasubramanian, A. Howes, M. Hallek, . ,
520    9_
$a BACKGROUND: Most patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma relapse after initial therapy. Bendamustine plus rituximab is often used in the relapsed or refractory setting. We assessed the efficacy and safety of adding ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rituximab in patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma. METHODS: The HELIOS trial was an international, double-blind, placebo-controlled, phase 3 study in adult patients (≥18 years of age) who had active chronic lymphocytic leukaemia or small lymphocytic lymphoma with measurable lymph node disease (>1·5 cm) by CT scan, and had relapsed or refractory disease following one or more previous lines of systemic therapy consisting of at least two cycles of a chemotherapy-containing regimen, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and adequate bone marrow, liver, and kidney function. Patients with del(17p) were excluded because of known poor response to bendamustine plus rituximab. Patients who had received previous treatment with ibrutinib or other BTK inhibitors, refractory disease or relapse within 24 months with a previous bendamustine-containing regimen, or haemopoietic stem-cell transplant were also excluded. Patients were randomly assigned (1:1) by a web-based system to receive bendamustine plus rituximab given in cycles of 4 weeks' duration (bendamustine: 70 mg/m(2) intravenously on days 2-3 in cycle 1, and days 1-2 in cycles 2-6; rituximab: 375 mg/m(2) on day 1 of cycle 1, and 500 mg/m(2) on day 1 of cycles 2-6 for a maximum of six cycles) with either ibrutinib (420 mg daily orally) or placebo until disease progression or unacceptable toxicity. Patients were stratified according to whether they were refractory to purine analogues and by number of previous lines of therapy. The primary endpoint was independent review committee (IRC)-assessed progression-free survival. Crossover to ibrutinib was permitted for patients in the placebo group with IRC-confirmed disease progression. Analysis was by intention-to-treat and is continuing for further long-term follow-up. The trial is registered with ClinicalTrials.gov, number NCT01611090. FINDINGS: Between Sept 19, 2012, and Jan 21, 2014, 578 eligible patients were randomly assigned to ibrutinib or placebo in combination with bendamustine plus rituximab (289 in each group). The primary endpoint was met at the preplanned interim analysis (March 10, 2015). At a median follow-up of 17 months (IQR 13·7-20·7), progression-free survival was significantly improved in the ibrutinib group compared with the placebo group (not reached in the ibrutinib group (95% CI not evaluable) vs 13·3 months (11·3-13·9) in the placebo group (hazard ratio [HR] 0·203, 95% CI 0·150-0·276; p<0·0001). IRC-assessed progression-free survival at 18 months was 79% (95% CI 73-83) in the ibrutinib group and 24% (18-31) in the placebo group (HR 0·203, 95% CI 0·150-0·276; p<0·0001). The most frequent all-grade adverse events were neutropenia and nausea. 222 (77%) of 287 patients in the ibrutinib group and 212 (74%) of 287 patients in the placebo group reported grade 3-4 events; the most common grade 3-4 adverse events in both groups were neutropenia (154 [54%] in the ibrutinib group vs 145 [51%] in the placebo group) and thrombocytopenia (43 [15%] in each group). A safety profile similar to that previously reported with ibrutinib and bendamustine plus rituximab individually was noted. INTERPRETATION: In patients eligible for bendamustine plus rituximab, the addition of ibrutinib to this regimen results in significant improvements in outcome with no new safety signals identified from the combination and a manageable safety profile. FUNDING: Janssen Research & Development.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a anemie $x chemicky indukované $7 D000740
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a fibrilace síní $x chemicky indukované $7 D001281
650    _2
$a bendamustin hydrochlorid $x aplikace a dávkování $7 D000069461
650    _2
$a progrese nemoci $7 D018450
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a krvácení $x chemicky indukované $7 D006470
650    _2
$a lidé $7 D006801
650    _2
$a analýza podle původního léčebného záměru $7 D057194
650    _2
$a chronická lymfatická leukemie $x farmakoterapie $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nauzea $x chemicky indukované $7 D009325
650    _2
$a neutropenie $x chemicky indukované $7 D009503
650    _2
$a pyrazoly $x aplikace a dávkování $x škodlivé účinky $7 D011720
650    _2
$a pyrimidiny $x aplikace a dávkování $x škodlivé účinky $7 D011743
650    _2
$a opakovaná terapie $7 D019233
650    _2
$a rituximab $x aplikace a dávkování $7 D000069283
650    _2
$a trombocytopenie $x chemicky indukované $7 D013921
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cramer, Paula $u Department I of Internal Medicine and German CLL Study Group, University of Cologne, Cologne, Germany.
700    1_
$a Demirkan, Fatih, $d 1965- $u Division of Hematology, Dokuz Eylul University, Izmir, Turkey. $7 xx0316387
700    1_
$a Fraser, Graeme $u Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
700    1_
$a Silva, Rodrigo Santucci $u IEP São Lucas/Hemomed Oncologia e Hematologia, São Paulo, Brazil.
700    1_
$a Grosicki, Sebastian $u Department of Cancer Prevention, Faculty of Public Health, Silesian Medical University, Katowice, Poland.
700    1_
$a Pristupa, Aleksander $u Regional Clinical Hospital, Ryazan, Russia.
700    1_
$a Janssens, Ann $u Universitaire Ziekenhuizen Leuven, Leuven, Belgium.
700    1_
$a Mayer, Jiri $u Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital Brno, Jihlavska, Brno, Czech Republic.
700    1_
$a Bartlett, Nancy L $u Washington University School of Medicine, Siteman Cancer Center, St Louis, MO, USA.
700    1_
$a Dilhuydy, Marie-Sarah $u Hôpital Haut-Lévêque, Bordeaux, Pessac, France.
700    1_
$a Pylypenko, Halyna $u Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine.
700    1_
$a Loscertales, Javier $u Hematology Department, Hospital Universitario La Princesa, IIS-IP, Madrid, Spain.
700    1_
$a Avigdor, Abraham $u Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, University of Tel-Aviv, Tel-Aviv, Israel. $7 gn_A_00010353
700    1_
$a Rule, Simon $u Department of Haematology, Derriford Hospital, Plymouth, UK.
700    1_
$a Villa, Diego $u Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
700    1_
$a Samoilova, Olga $u Nizhny Novogorod Regional Clinical Hospital, Nizhny Novogorod, Russia.
700    1_
$a Panagiotidis, Panagiots $u 1st Department of Propedeutic Medicine, University of Athens, Athens, Greece.
700    1_
$a Goy, Andre $u John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
700    1_
$a Mato, Anthony $u John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA; Center for CLL, University of Pennsylvania, Philadelphia, PA, USA.
700    1_
$a Pavlovsky, Miguel A $u Department of Hematology, Fundaleu, Buenos Aires, Argentina.
700    1_
$a Karlsson, Claes $u Department of Hematology, Karolinska University Hospital, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Mahler, Michelle $u Janssen Research & Development, Raritan, NJ, USA.
700    1_
$a Salman, Mariya $u Janssen Research & Development, Raritan, NJ, USA.
700    1_
$a Sun, Steven $u Janssen Research & Development, Raritan, NJ, USA.
700    1_
$a Phelps, Charles $u Janssen Research & Development, Raritan, NJ, USA.
700    1_
$a Balasubramanian, Sriram $u Janssen Research & Development, Spring House, PA, USA.
700    1_
$a Howes, Angela $u Janssen Research & Development, High Wycombe, UK.
700    1_
$a Hallek, Michael $u Department I of Internal Medicine, Center of Integrated Oncology, University of Cologne and Cologne Cluster of Excellence in Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.
700    1_
$a ,
773    0_
$w MED00011558 $t Lancet oncology $x 1474-5488 $g Roč. 17, č. 2 (2016), s. 200-11
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26655421 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20240418102308 $b ABA008
999    __
$a ok $b bmc $g 1154770 $s 944628
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 17 $c 2 $d 200-11 $e 20151205 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...